Back to top

Moderna’s experimental vaccine is 94.5% effective

Vaccine success gives world more hope

Moderna’s experimental vaccine is 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial, the company said, becoming the second U.S. drugmaker to report results that far exceed expectations.

Together with Pfizer’s vaccine, which is also more than 90% effective, and pending more safety data and regulatory review, the United States could have two vaccines authorized for emergency use in December with as many as 60 million doses of vaccine available this year.